2 results
Approved WMOPending
Our primary aim is to assess the (cost-)effects of the ACCESS system in the support of exacerbation self-management of patients with COPD.
Approved WMOCompleted
Primary objective:To demonstrate the higher efficacy of small particles Foster® 100/6 (two puffs b.i.d.) versus large particles Symbicort® 200/6 (two inhalations b.i.d.), in terms of residual volume reduction in patients with chronic obstructive…